Literature DB >> 6282198

Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus.

H Lagast, S H Zinner, J Klastersky.   

Abstract

Serum bactericidal activity was determined against 10 strains each of Pseudomonas aeruginosa and Staphylococcus aureus in serum from volunteers 1 and 6 h after intravenous infusion of cefotaxime, tobramycin, and the combination; or of moxalactam, tobramycin, and the combination. High serum bactericidal activity against P. aeruginosa was found significantly more frequently with moxalactam plus tobramycin than with cefotaxime, moxalactam, and tobramycin alone or with cefotaxime plus tobramycin.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6282198      PMCID： PMC181739          DOI： 10.1128/AAC.20.4.539

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections.

Authors:  J Klastersky; D Daneau; G Swings; D Weerts
Journal:  J Infect Dis       Date:  1974-02       Impact factor: 5.226

2.  Pharmacology of a new 1-oxa-beta-lactam (LY127935) in normal volunteers.

Authors:  J N Parsons; J M Romano; M E Levison
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

3.  Use of sodium polyanethol sulfonate to selectively inhibit aminoglycoside and polymyxin antibiotics in a rapid blood level antibiotic assay.

Authors:  S C Edberg; C J Bottenbley; K Gam
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

4.  Antibacterial activity of a new parenteral cephalosporin--HR 756: comparison with cefamandole and ceforanide.

Authors:  G W Counts; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

5.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

6.  Significance of antimicrobial synergism for the outcome of gram negative sepsis.

Authors:  J Klastersky; F Meunier-Carpentier; J M Prevost
Journal:  Am J Med Sci       Date:  1977 Mar-Apr       Impact factor: 2.378

7.  Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.

Authors:  P R Murray
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

8.  Cefotaxime kinetics after intravenous and intramuscular injection of single and multiple doses.

Authors:  H C Neu; P Aswapokee; K P Fu; I Ho; C Matthijssen
Journal:  Clin Pharmacol Ther       Date:  1980-05       Impact factor: 6.875

9.  Comparison of in vitro activity of moxalactam (LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticarcillin against 420 blood culture isolates.

Authors:  L G Reimer; S Mirrett; L B Reller
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

10.  LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191
View more
  7 in total

1.  Evaluation of novel antipseudomonal drugs using the serum bactericidal activity test.

Authors:  I Braveny; K Machka; D Milatovic
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

2.  Comparative study of serum bactericidal activity of cefotaxime alone or in combination with tobramycin.

Authors:  M G Bergeron; M LeBel; A Charest; J F Forcier; J Morin; F Vallée
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

3.  Serum bactericidal test in volunteers--a review.

Authors:  S C Schimpff; G L Drusano; H C Standiford
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

Review 4.  Cephalosporins in gram-positive infections.

Authors:  J Symonds; A M Geddes
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 5.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

6.  Bactericidal and synergistic activity of moxalactam alone and in combination with gentamicin against Pseudomonas aeruginosa.

Authors:  P K Yu; R S Edson; J A Washington; P E Hermans
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

7.  Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.

Authors:  L C Preheim; R G Penn; C C Sanders; R V Goering; D K Giger
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.